Transoral laser microsurgery (TLM) ± adjuvant therapy for advanced stage oropharyngeal Cancer: Outcomes and prognostic factors

Laryngoscope

Volumn 119, Issue 9, 2009, Pages 1709-1719

  Rich, Jason T ^a   Milov, Simon ^a   Lewis Jr , James S ^a   Thorstad, Wade L ^a   Adkins, Douglas R ^a   Haughey, Bruce H ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Otolaryngology Head and Neck Surgery   (United States)

Author keywords

Advanced stage oropharyngeal cancer; Chemoradiotherapy; Human papilloma virus; P16; Tongue base; Tonsil; Transoral laser microsurgery

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE NECROSIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ESOPHAGUS STENOSIS; FEMALE; FOLLOW UP; HUMAN; LASER SURGERY; MAJOR CLINICAL STUDY; MALE; NECK DISSECTION; OROPHARYNX CANCER; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; RADIATION NECROSIS; SURVIVAL TIME; SWALLOWING; TRANSORAL LASER MICROSURGERY; TREATMENT FAILURE; TREATMENT OUTCOME; TRISMUS; VIRUS DETECTION; WART VIRUS;

ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; DEGLUTITION; FEMALE; HUMANS; LASER THERAPY; LYMPH NODE EXCISION; MALE; MICROSURGERY; MIDDLE AGED; NEOPLASM STAGING; OROPHARYNGEAL NEOPLASMS; POSTOPERATIVE PERIOD; PROGNOSIS; SURVIVAL ANALYSIS; TONGUE NEOPLASMS; TONSILLAR NEOPLASMS; TREATMENT OUTCOME;

EID: 70349587706     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20552     Document Type: Article

References (41)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma increasing trends in the U.S. population ages 20-44 years. Cancer 2005;103:1843-1849
3. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-720.
4. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349: 2091-2098
5. Garden AS, Harris J, Trotti A, et al. Long-term results of concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: A phase II trial of the radiation therapy oncology group (RTOG 99-14). Int J Radiat Oncol Biol Phys 2008;71:1351-1355.
6. Nguyen NP, Moltz CC, Frank C. Dysphagia following chemoradiation for locally advanced head and neck cancer. Ann Oncol 2004;15:383-388.
7. Steiner W, Fierek O, Ambrosch P, Hommerich CP, Kron M. Transoral laser microsurgery for squamous cell carcinoma of the base of tongue. Arch Otolaryngol Head Neck Surg 2003;129:36-43.
8. Hinni ML, Salassa JR, Grant DG, et al. Transoral laser microsurgery for advanced laryngeal cancer. Arch Otolaryngol Head Neck Surg 2007;133:1198-1204.
9. Vaughan CW, Strong MS, Shapshay SM. Modern technology in cancer therapy: Status of the carbon dioxide laser. Otolaryngol Clin North Am 1980;13:459-465.
10. Steiner W, Ambrosch P, Knappe MV. Endoscopic Laser Surgery of the Upper Aerodigestive Tract: With Special Emphasis on Cancer Surgery. New York, NY: Thieme Medical Publishers; 2001.
11. Munger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004; 78:11451-11460.
12. Jones DL, Alani RM, Munger K. The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21CIP1-mediated inhibition of cdk2. Genes Dev 1997;11: 2101-2111.
13. Salassa JR. A functional outcome swallowing scale for staging oropharyngeal dysphagia. Dig Dis 1999;17:230-234.
14. Sharp CM, Borg HK, Kishore A, MacKenzie K. Hypoglossal nerve paralysis following tonsillectomy. J Laryngol Otol 2002;116:389-391.
15. Cooper JS, Pajak TF, Forastiere A, et al. Precisely defining high-risk operable head and neck tumors based on RTOG #85-03 and #88-24: Targets for postoperative radiochemotherapy? Head Neck 1998;20:588-594.
16. Cooper JS, Pajak TF, Forastiere A, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the nead and neck. N Engl J Med 2004;350:1937-1944.
17. Sumer BD, Gastman BR, Haughey BH, et al. Microvascular flap reconstruction of major pharyngeal resections with intent of laryngeal preservation. Arch Otolaryngol Head Neck Surg In press, 2009.
18. Zelefsky MJ, Harrison LB, Armstrong JG. Long-term treatment results of postoperative radiation therapy for advanced stage oropharyngeal carcinoma. Cancer 1992:70:2388-2395.
19. Wolf GT, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer: The department of veterans affairs laryngeal cancer study group. N Engl J Med 1991; 324:1685-1690
20. Forastiere AA, Maor M, Weber RS. Long-term results of Intergroup RTOG 91-11: A phase III trial to preserve the larynx-induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol 2006;24(18 suppl):5517.
21. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. J Clin Oncol 2008;26:3582-3589.
22. Zafereo ME, Hanasono MM, Rosenthal DI, et al. The role of salvage surgery in recurrent oropharyngeal squamous cell carcinoma. Paper presented at: 7th International Conference on Head and Neck Cancer; July 19-23, 2008; San Francisco, CA. Abstract S269.
23. Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21:92-98.
24. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced stage oropharynx carcinoma. J Natl Cancer Inst 1999;91:2081-2086.
25. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76.
26. Nguyen NP, Vos P, Smith HJ, et al. Concurrent chemoradiation for locally advanced oropharyngeal cancer. Am J Otolaryngol 2007;28:3-8.
27. Urba SG, Moon J, Giri S, et al. Organ preservation for advanced resectable cancer of the base of tongue and hypopharynx: A southwest oncology group trial. J Clin Oncol 2005;23:88-95.
28. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: Response and survival positively associated with HPV16 copy number. J Clin Oncol 2008;26:1-11.
29. Huang K, Xia P, Chuang C, et al. Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma the University of California-San Francisco experience. Cancer 2008;113:497-507.
30. Haughey BH, Taylor M. Fasciocutaneous flap reconstruction of the tongue and floor of mouth outcomes and techniques. Arch Otolaryngol Head Neck Surg 2002;128: 1388-1395.
31. Machtay M, Rosenthal DI, Hershock D, et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: A University of Pennsylvania phase II trial. J Clin Oncol 2002;20:3964-3971.
32. Cmelak AJ, Li S, Goldwasser MA, et al. Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: Results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol 2007;25:3971-3977.
33. Greven KM, White DR, Browne JD, et al. Swallowing dysfunction is a common sequelae after chemoradiation for oropharynx carcinoma. Am J Clin Oncol 2008;31:209-212.
34. Yom SS, Machtay M, Biel MA, et al. Survival impact of planned restaging and early surgical salvage following definitive chemoradiation for locally advanced squamous cell carcinomas of the oropharynx and hypopharynx. Am J Clin Oncol 2005;28:385-392.
35. Bernier J, Cooper JS, Pajak TF, et al. Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (#9501). Head Neck 2005;27:843-850.
36. Pignon JP, Bourhis J. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): An update. Int J Radiat Oncol Biol Phys 2007;69:S112-S114. (Pubitemid 47369400)
37. von Knebel Doeberitz M. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. Eur J Cancer 2002;38: 2229-2242.
38. Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. Effect of HPV-associated p16INK4a expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009;27:1992-1998.
39. Smith EM, Wang D, Kim Y, et al. P16INK4a expression, human papillomavirus, and survival in head and neck cancer. Oral Oncol 2008;44:133-142. (Pubitemid 351179656)
40. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-269.
41. Hall JC, Hall JL. Emergence of 'Retropro' studies in the surgical literature. ANZ J Surg 2008;78:411-413.